Photocure ASA (PHO.OL)
- Previous Close
50.00 - Open
50.10 - Bid 49.90 x 140900
- Ask 50.00 x 97900
- Day's Range
49.70 - 50.40 - 52 Week Range
47.00 - 69.00 - Volume
51,992 - Avg. Volume
73,605 - Market Cap (intraday)
1.33B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.12 - Earnings Date Jul 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 23, 2013
- 1y Target Est
82.50
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
www.photocure.com99
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PHO.OL
View MorePerformance Overview: PHO.OL
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHO.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHO.OL
View MoreValuation Measures
Market Cap
1.33B
Enterprise Value
1.06B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.58
Price/Book (mrq)
2.65
Enterprise Value/Revenue
2.01
Enterprise Value/EBITDA
16.23
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.64%
Return on Assets (ttm)
1.76%
Return on Equity (ttm)
-0.68%
Revenue (ttm)
525.39M
Net Income Avi to Common (ttm)
-3.34M
Diluted EPS (ttm)
-0.12
Balance Sheet and Cash Flow
Total Cash (mrq)
288.83M
Total Debt/Equity (mrq)
3.35%
Levered Free Cash Flow (ttm)
39.08M